Human Rights, Ethical Leadership, Wall Street, Business Ethics, Corporate Governance, Pharmaceutical Industry Ethics, Intellectual Property, and Corporate Social Responsibility in China.
Professor Santoro is often quoted in top-tier media such CNN and The New York Times, and he has blogged in the Huffington Post.
Prof. Santoro’s latest book, written with Ronald J. Strauss, is Wall Street Values: Business Ethics and the Global Financial Crisis (Cambridge University Press, 2013). Alan Blinder, former Vice Chair of the Federal Reserve Board wrote: “The financial crisis has been examined from every angle except this one: the ethiccal lapses that led up to it. Time spent reading this highly original book is time well spent. It will make you think.”
Professor Santoro’s first book Profits and Principles: Global Capitalism and Human Rights in China (Cornell, 2000) was widely praised in, among other places, in The New York Times Book Review and Foreign Affairs.
His next book, China 2020: How Western Business Can–and Should–Influence Social and Political Change was published by Cornell University Press in 2009. Santoro is also co-editor (with Tom Gorrie, Corporate Vice President Government Affairs and Policy for Johnson & Johnson) of Ethics and the Pharmaceutical Industry (Cambridge University Press, 2005).
Prof. Santoro has served as a consultant to the Global Business Coalition on HIV/AIDS, Malaria, and Tuberculosis, helping in that capacity to design an industry-wide corporate integrity program for companies supplying long lasting anti-malaria bednets. He also worked with Arusha-based A to Z Corporation to design, adopt and implement one of the first business ethics code of conduct in Tanzania. His expert testimony in the Vioxx litigation became the basis for court-ordered corporate governance reforms adopted by Merck.
Prof. Santoro was named “Professor of the Year” by Rutgers MBA students in 2013. He is a Fellow of the RBS Teaching Excellence Center. He has been a visiting Professor at the Shanghai Advanced Institute of Finance and the University of Zurich, as well as an Adjunct Lecturer and a Teaching Fellow at Harvard’s John F. Kennedy School of Government where he taught ethics and economics courses. As a Research Associate at Harvard Business School, he wrote or co-authored nearly thirty case studies and teaching notes on ethical and legal topics, including a leading case on the introduction of intellectual property into the WTO. He was an invited speaker at the American Bar Association Conference on Professionalism in the 21st Century. He was the recipient of research grant from the Aspen Institute’s Initiative for Social Innovation through Business and he has also served as a GE Teaching Fellow at Rutgers Business School.
Prof. Santoro is a co-founding editor of Business and Human Rights Journal which will be published by Cambridge University Press commencing in 2016. He serves on the Editorial Board of Business Ethics Quarterly and the Journal of Human Rights, and he is a member of the Board of Directors of the NASBA Center for the Public Trust.
Professor Santoro testified before the United States Senate Finance Committee on the human rights implications of China’s entry into the World Trade Organization. He is a frequent featured speaker on human rights and business ethics at numerous venues, including Cornell, Columbia, Oberlin, Princeton, Redlands, Santa Clara, and Tufts , as well as at the Brookings Institution, the World Affairs Council, the Economic Strategy Institute, the Association of the Bar of the City of New York, and the Asia Society.
Prof. Santoro was a Fulbright Fellow at the University of Hong Kong during the 1993-94 academic year and he travels frequently to Asia. In the summer, he has taught executive MBA courses in Business Strategy and Business Law in Beijing and Shanghai and at the Sinopec Management Institute.
Prior to entering academe, Santoro practiced law. During law school he was a clerk at Skadden Arps Slate Meagher & Flom. He was summer associate at Shearman & Sterling and an associate at Webster & Sheffield. He has been the General Counsel of BioTechnica International in Cambridge, Massachusetts, one of the first publicly-held biotechnology companies, and of Finevest (now Interlaken Capital) in Greenwich, Connecticut, a privately held venture firm.